EICHORPublic-registry site landscape for NCT05164471, “Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B”, a Hemophilia B study sponsored by Spur Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05164471 (registry record) |
| Study title | Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B |
| Official title | A Dose Confirmation Study of FLT180a (Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene) in Adult Subjects With Hemophilia B |
| Sponsor | Spur Therapeutics |
| Condition(s) | Hemophilia B |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 7 |
| Site countries | United States, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT05164471.
Eichor generates a preliminary site-risk snapshot for NCT05164471 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Hemophilia B trials
More from Spur Therapeutics
← Eichor home · All tracked trials · Hemophilia B studies · Weekly briefs
